# Do GLP-1s cause cancer? The thyroid warning and the studies

Source: https://pepvault.app/guides/do-glp-1s-cause-cancer

Last updated: 2026-11-20

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [GLP-1s](https://pepvault.app/guides#glp1)

# Do GLP-1s cause cancer? The thyroid warning and what the studies show

Reviewed November 2026 21 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

The thyroid warning on Ozempic, Wegovy, Mounjaro and Zepbound comes from rats. What human studies, FDA and EMA found on thyroid, pancreatic and other cancers.

- **Last reviewed:** Nov 20, 2026
- **Sources:** 21
- **Questions:** 8
- **Compounds:** 3

## The short answer

No study has shown that Ozempic, Wegovy, Mounjaro or Zepbound cause cancer in people. Their boxed thyroid warning comes from rats and mice, and the labels rule all four out for anyone with a personal or family history of medullary thyroid cancer or MEN 2. Human studies split on thyroid cancer, and a 48-trial review found little or no effect on thyroid, pancreatic, breast or kidney cancer.

- The boxed warning on all four labels comes from thyroid tumors in mice and rats; its relevance to people has not been determined.
- Health-record studies split on thyroid cancer; the US rise came in the first year, which its authors said may have been due to earlier detection.
- Pancreatic cancer did not rise in an Israeli 7-year study, in six semaglutide trials or in a 48-trial review.
- A personal or family history of medullary thyroid cancer, or MEN 2, rules all four drugs out; any other history is the prescriber's call.

Every number checked at its primary source · Nov 20, 2026 · [21 sources](https://pepvault.app/guides/do-glp-1s-cause-cancer#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** The warning rests on 2-year rodent studies; the human evidence is health-record studies of up to 2.6 million people and pooled randomized trials, mostly 1 to 5 years long and not designed to count cancer.

## What does the cancer warning on Ozempic, Wegovy, Mounjaro and Zepbound say?

All four labels open with the same **boxed warning** (pepvault.app/glossary/boxed-warning), the FDA's strongest label warning: "Risk of thyroid C-cell tumors". C-cells are the thyroid cells that make the hormone calcitonin, and the cancer they can form is medullary thyroid carcinoma (MTC), a rare thyroid cancer. Ozempic's words: "In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans"[1](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-1). Wegovy says the same of semaglutide[2](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-2); Mounjaro and Zepbound say it of tirzepatide in rats[3](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-3) [4](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-4).

| Label (current version) | Animals with tumors | What the 2-year studies found | Who must not use it |
| --- | --- | --- | --- |
| Ozempic, semaglutide (June 1, 2026) | Mice and rats | More C-cell adenomas (benign tumors) in both sexes of both species; more carcinomas in male rats[1](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-1) | A personal or family history of MTC, or MEN 2[1](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-1) |
| Wegovy, semaglutide (June 18, 2026) | Mice and rats | The same: adenomas at every dose in both species; carcinomas in male rats, at up to 0.7 times the human exposure[2](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-2) | The same[2](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-2) |
| Mounjaro, tirzepatide (August 27, 2026) | Rats, both sexes | Adenomas and carcinomas combined rose at every dose, 0.1 to 1 times the human exposure; none in a 6-month study of transgenic mice[3](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-3) | The same[3](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-3) |
| Zepbound, tirzepatide (August 28, 2026) | Rats, both sexes | The same as Mounjaro[4](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-4) | The same[4](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-4) |

MEN 2 (multiple endocrine neoplasia type 2) is an inherited condition that makes MTC likely, which is why it is a **contraindication** (pepvault.app/glossary/contraindication), a reason not to use the drug at all[1](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-1) [2](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-2) [3](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-3) [4](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-4). The semaglutide labels add that MTC cases have been reported in people on liraglutide, an older GLP-1, and that those reports are "insufficient to establish or exclude a causal relationship"[1](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-1) [2](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-2). The brand pages hold each label in full: pepvault.app/drugs/ozempic, pepvault.app/drugs/wegovy, pepvault.app/drugs/mounjaro and pepvault.app/drugs/zepbound.

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

If you notice anything new while on a GLP-1, PepVault's side-effect log keeps each symptom with its date and severity, next to the doses you logged.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## Why do rats get thyroid tumors on GLP-1 drugs?

Rat C-cells carry plenty of the GLP-1 receptor, the switch these drugs press; human and monkey C-cells carry little. Novo Nordisk scientists showed in 2010 that the drugs made rodent C-cells release calcitonin and multiply, while 20 months of liraglutide at over 60 times the human exposure caused no C-cell growth in monkeys[5](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-5). The full rodent story is at pepvault.app/guides/retatrutide-and-cancer.

Species note: the tumors are a finding in mice and rats. Every label says their relevance to people "has not been determined"[1](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-1) [2](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-2) [3](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-3) [4](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-4).

## Do GLP-1s cause thyroid cancer in people?

Seven major studies split, and the absolute numbers are small either way. In the table, a result above 1 means more thyroid cancer on a GLP-1 and below 1 means less; when the range in brackets (the **confidence interval**, pepvault.app/glossary/confidence-interval) crosses 1, the study found no clear difference. The first four are **observational studies** (pepvault.app/glossary/observational-study) of health records; the last three pool randomized trials.

| Study | Who | Thyroid cancer result (95% range) |
| --- | --- | --- |
| France, 2023[6](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-6) | 2,562 people with thyroid cancer and 45,184 matched controls, all with type 2 diabetes | 1 to 3 years of use: 1.58 (1.27 to 1.95); MTC 1.78 (1.04 to 3.05) |
| Denmark, Norway and Sweden, 2024[7](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-7) | 145,410 GLP-1 users against 291,667 users of DPP-4 inhibitors, another diabetes drug; mean 3.9 years | 0.93 (0.66 to 1.31); MTC 1.19 (0.37 to 3.86) |
| Six countries, 2025[8](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-8) | 98,147 GLP-1 users against 2,488,303 DPP-4 inhibitor users; median 1.8 to 3.0 years | 0.81 (0.59 to 1.12); no rise with higher total dose |
| United States, 2025[9](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-9) | 351,913 adults with type 2 diabetes, 41,112 of them starting a GLP-1 | Overall 1.24 (0.88 to 1.76); first year 1.85 (1.11 to 3.08) |
| 64 trials, 2024[10](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-10) | Randomized trials lasting 52 weeks or more | 1.52 (1.01 to 2.29); MTC 1.44 (0.23 to 9.16) |
| 50 trials, 2025[21](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-21) | Diabetes and obesity trials lasting 52 weeks or more | 1.55 (1.05 to 2.27), clearer in the longer trials |
| 48 trials, 2026[11](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-11) | 94,245 people in placebo-controlled trials, semaglutide and tirzepatide included | 1.37 (0.82 to 2.31): 1 fewer to 9 more cases per 10,000 treated |

In the US study, thyroid cancer was diagnosed in 0.17% of people who started a GLP-1, against 0.17% to 0.23% on three other diabetes drugs, and the rise was clear only within the first year after starting, which the authors said "may have been due to enhanced early detection"[9](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-9): a new drug brings more check-ups, and more check-ups can find small thyroid cancers that were already there. The Scandinavian rates: 1.33 cases per 10,000 person-years on a GLP-1, 1.46 on the comparison drug[7](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-7).

The 2024 trial pool's rise rests on a single case (a fragility index of 1): one extra thyroid cancer for every 1,349 people treated for five years[10](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-10). The 2025 pool of 50 trials found a similar rise, clearer in trials of two years or more[21](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-21). The 2026 review, which kept only placebo-controlled trials and is the largest so far, rated the evidence moderate and found little or no effect[11](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-11). For MTC itself the cases are few: the French study found a rise, and the Scandinavian study and the 2024 trial pool found no clear difference[6](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-6) [7](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-7) [10](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-10).

<!--promo-->

If you notice anything new while on a GLP-1, PepVault's side-effect log keeps each symptom with its date and severity, next to the doses you logged. [Log it in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-do-glp-1s-cause-cancer-inline&mt=8)

<!--/promo-->

## With this guide

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)
- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)

### Studies

- [Semaglutide: 11.85% more weight loss than placebo without diabetes](https://pepvault.app/research/semaglutide-tan-2022)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 31 studies](https://pepvault.app/research#semaglutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Liraglutide vs Semaglutide](https://pepvault.app/peptides/compare/liraglutide-vs-semaglutide)
- [Semaglutide vs Dulaglutide](https://pepvault.app/peptides/compare/semaglutide-vs-dulaglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)
- [Constipation on Ozempic, Mounjaro or Zepbound: how common, and what helps](https://pepvault.app/guides/constipation-on-a-glp-1)
- [Nausea on Ozempic, Wegovy, Mounjaro or Zepbound: when it peaks and what helps](https://pepvault.app/guides/nausea-on-a-glp-1)
- [Headaches on a GLP-1: how common they were in the trials](https://pepvault.app/guides/headaches-on-a-glp-1)
- [Sulfur burps on Ozempic or Mounjaro: why they happen](https://pepvault.app/guides/sulfur-burps-on-a-glp-1)
- [GLP-1s and the gallbladder: gallstones, and taking one without a gallbladder](https://pepvault.app/guides/glp-1s-and-the-gallbladder)
- [GLP-1s and the heart: heart rate, blood pressure and the SELECT trial](https://pepvault.app/guides/glp-1s-and-the-heart)
- [Retatrutide and cancer: what the warning and the studies say](https://pepvault.app/guides/retatrutide-and-cancer)
- [Retatrutide and muscle loss: what the studies measured](https://pepvault.app/guides/retatrutide-and-muscle)

### Terms on this page

- [Unit (on a syringe)](https://pepvault.app/glossary/syringe-units)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Contraindication](https://pepvault.app/glossary/contraindication)
- [Boxed warning](https://pepvault.app/glossary/boxed-warning)
- [Confidence interval](https://pepvault.app/glossary/confidence-interval)
- [Incretin](https://pepvault.app/glossary/incretin)

## What did the FDA and EMA conclude?

- **EMA, thyroid, October 2023.** After the French study, the EMA's safety committee (PRAC) reviewed the published studies and the makers' data, and concluded that "the available evidence does not support a causal association" between the five GLP-1 drugs it reviewed (semaglutide among them, tirzepatide not) and thyroid cancer. It saw no reason to change the product information[12](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-12).
- **EMA, pancreas, July 2013.** After a study of a small number of pancreas samples from organ donors, the EMA's medicines committee found that trial data "do not indicate an increased risk" of pancreatic cancer, while the number of cases was too small for final conclusions[13](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-13).
- **FDA and EMA, February 2014.** The two agencies' joint review of pancreatic safety for incretin drugs (pepvault.app/glossary/incretin), the family GLP-1s belong to, appeared in the New England Journal of Medicine[14](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-14).
- **FDA, as of November 20, 2026.** The boxed thyroid warning stays on all four US labels, in their 2026 versions[1](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-1) [2](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-2) [3](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-3) [4](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-4), and a US registry run by Novo Nordisk with Eli Lilly and AstraZeneca counts new adult MTC cases each year to catch any rise tied to GLP-1 drugs; it is planned to run to 2039[15](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-15).

## Do GLP-1s cause pancreatic cancer?

The large studies have found no rise in pancreatic cancer on a GLP-1. An Israeli study followed 543,595 adults with diabetes for up to seven years and found no rise against basal insulin: 0.52 (0.19 to 1.41) from the fifth year after starting[16](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-16). Six placebo-controlled semaglutide trials with 38,057 people counted 32 pancreatic cancers on the drug and 41 on placebo, an odds ratio of 0.78 (0.49 to 1.24)[17](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-17). Across 48 trials of GLP-1 and dual agonists, the result was 0.84 (0.53 to 1.35)[11](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-11).

The pancreas warning that is on the labels is for pancreatitis, an inflammation of the pancreas, which is rare; it is covered at pepvault.app/guides/are-glp-1s-safe-long-term, with the other long-term risks.

## Can a GLP-1 lower the risk of other cancers?

Excess body fat causes at least 13 cancers, the WHO's cancer agency (IARC) concluded in 2016 after more than a thousand studies: cancers of the esophagus, upper stomach, colon and rectum, liver, gallbladder, pancreas, breast after menopause, womb, ovary, kidney and thyroid, plus meningioma and multiple myeloma[18](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-18). Its group wrote that evidence for intentional weight loss lowering cancer "in humans remains to be established"[18](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-18).

| Study | Who | What it found |
| --- | --- | --- |
| US health records, 2024[19](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-19) | 1,651,452 adults with type 2 diabetes | Against insulin: lower risk of 10 of 13 obesity-linked cancers, pancreatic 0.41 and colorectal 0.54 among them. Against metformin: none lower, kidney cancer higher, 1.54 (1.27 to 1.87) |
| Florida health records, 2025[20](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-20) | 86,632 adults with obesity, half on a GLP-1 | 14 cancers at 13.6 against 16.4 per 1,000 person-years, 0.83 (0.76 to 0.91); womb 0.75, ovary 0.53, meningioma 0.69; kidney 1.38 (0.99 to 1.93) |
| 50 trials, 2025[21](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-21) | Diabetes and obesity trials of 52 weeks or more | Overall cancer 1.05 (0.98 to 1.13); fewer uterine cancers in the obesity trials |
| 48 trials, 2026[11](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-11) | 94,245 people, placebo-controlled | Little or no effect on breast and kidney cancer (moderate certainty) and on most others (low certainty); stomach cancer very uncertain |

The record studies mostly point to fewer cancers, the trials to no change; the trials are short and were not built to count cancer[11](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-11). The 2025 trial pool also found a rise in colorectal cancer in the shorter trials only, which its authors suggest may come from more bowel tests prompted by the drugs' stomach side effects[21](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-21). No GLP-1 is approved to prevent cancer.

## Can you take a GLP-1 with a family history of thyroid cancer?

The labels draw one line: a personal or family history of medullary thyroid carcinoma, or MEN 2, rules all four drugs out[1](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-1) [2](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-2) [3](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-3) [4](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-4). They name no other cancer history. The more common thyroid cancers, such as papillary, are not in the contraindication, and the labels say routine calcitonin tests or thyroid ultrasounds are "of uncertain value" for catching MTC early and can lead to unnecessary procedures[1](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-1) [2](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-2). Whether a GLP-1 suits someone with a thyroid nodule, a past cancer or a relative with an unnamed thyroid cancer is the prescriber's decision, made with the label and your history.

**When to get help** The labels name the signs to report: a lump or swelling in the neck, trouble swallowing, shortness of breath, or hoarseness that does not go away; any of these is a reason to see your doctor[1](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-1) [3](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-3).

<!--promo-->

PepVault's doctor's report puts your doses, consistency, weight and logged side effects on one page to bring to that appointment. [Track your weight in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-do-glp-1s-cause-cancer-inline&mt=8)

<!--/promo-->

## What is still unknown about GLP-1s and cancer?

- **Decades of use.** Most studies follow people for 2 to 5 years, and cancers can take longer[7](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-7) [8](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-8) [11](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-11). The MTC registry is planned to run to 2039[15](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-15).
- **The kidney signal.** One record study found more kidney cancer against metformin, though less against insulin, and another a borderline rise against non-users[19](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-19) [20](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-20); the 2026 trial review found no clear difference[11](https://pepvault.app/guides/do-glp-1s-cause-cancer#source-11).
- **The newest drugs.** Retatrutide, still in trials, has no label; its cancer data are at pepvault.app/guides/retatrutide-and-cancer.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. OZEMPIC (semaglutide) injection, prescribing information. Novo Nordisk. DailyMed, version 20, effective June 1, 2026 (published June 10, 2026): boxed warning, 4, 5.1, 13.1. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79)
2. WEGOVY (semaglutide) injection and tablets, prescribing information. Novo Nordisk. DailyMed, version 19, effective June 18, 2026 (published June 30, 2026): boxed warning, 4, 5.1, 13.1. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b)
3. MOUNJARO (tirzepatide) injection, prescribing information. Eli Lilly. DailyMed, version 40, effective August 27, 2026 (published September 2, 2026): boxed warning, 4, 5.1, 13.1. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0)
4. ZEPBOUND (tirzepatide) injection, prescribing information. Eli Lilly. DailyMed, version 40, effective August 28, 2026 (published September 2, 2026): boxed warning, 4, 5.1, 13.1. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)
5. Bjerre Knudsen L et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010. [PubMed 20203154](https://pubmed.ncbi.nlm.nih.gov/20203154/)
6. Bezin J et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023. [PubMed 36356111](https://pubmed.ncbi.nlm.nih.gov/36356111/)
7. Pasternak B et al. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ. 2024. [PubMed 38683947](https://pubmed.ncbi.nlm.nih.gov/38683947/)
8. Baxter SM et al. Glucagon-like peptide 1 receptor agonists and risk of thyroid cancer: an international multisite cohort study. Thyroid. 2025. [PubMed 39772758](https://pubmed.ncbi.nlm.nih.gov/39772758/)
9. Brito JP et al. GLP-1RA use and thyroid cancer risk. JAMA Otolaryngol Head Neck Surg. 2025. [PubMed 39847346](https://pubmed.ncbi.nlm.nih.gov/39847346/)
10. Silverii GA et al. Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2024. [PubMed 38018310](https://pubmed.ncbi.nlm.nih.gov/38018310/)
11. Ko A et al. Risk for cancer with glucagon-like peptide-1 receptor agonists and dual agonists: a systematic review and meta-analysis. Ann Intern Med. 2026. [PubMed 41359966](https://pubmed.ncbi.nlm.nih.gov/41359966/)
12. European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 23-26 October 2023: GLP-1 receptor agonists, available evidence not supporting link with thyroid cancer. Published October 27, 2023. [ema.europa.eu](https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-23-26-october-2023)
13. European Medicines Agency. Investigation into GLP-1-based diabetes therapies concluded. July 26, 2013. [ema.europa.eu](https://www.ema.europa.eu/en/news/investigation-glp-1-based-diabetes-therapies-concluded)
14. Egan AG et al. Pancreatic safety of incretin-based drugs: FDA and EMA assessment. N Engl J Med. 2014. [PubMed 24571751](https://pubmed.ncbi.nlm.nih.gov/24571751/)
15. ClinicalTrials.gov NCT01511393. An active surveillance program for cases of medullary thyroid carcinoma (MTC). Sponsor Novo Nordisk, with AstraZeneca and Eli Lilly; estimated completion December 2039. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01511393)
16. Dankner R et al. Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk in patients with type 2 diabetes. JAMA Netw Open. 2024. [PubMed 38175642](https://pubmed.ncbi.nlm.nih.gov/38175642/)
17. Chiang CH et al. Semaglutide and risk of pancreatic cancer: a meta-analysis of randomised trials. Diabetes Obes Metab. 2026. [PubMed 42297743](https://pubmed.ncbi.nlm.nih.gov/42297743/)
18. Lauby-Secretan B et al.; IARC Handbook Working Group. Body fatness and cancer: viewpoint of the IARC Working Group. N Engl J Med. 2016. [PubMed 27557308](https://pubmed.ncbi.nlm.nih.gov/27557308/)
19. Wang L et al. Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. JAMA Netw Open. 2024. [PubMed 38967919](https://pubmed.ncbi.nlm.nih.gov/38967919/)
20. Dai H et al. GLP-1 receptor agonists and cancer risk in adults with obesity. JAMA Oncol. 2025. [PubMed 40839273](https://pubmed.ncbi.nlm.nih.gov/40839273/)
21. Silverii GA et al. GLP-1 receptor agonists and the risk for cancer: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2025. [PubMed 40437949](https://pubmed.ncbi.nlm.nih.gov/40437949/)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide · GLP-1

Guide · GLP-1

### [Retatrutide and cancer: what the warning and the studies say](https://pepvault.app/guides/retatrutide-and-cancer)

Retatrutide and cancer: where the GLP-1 thyroid warning comes from, who the trials left out, the cancers they counted, and what studies of the class found.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [Semaglutide Studied range: 0.25–2.4 mg](https://pepvault.app/peptides/semaglutide)
- [Tirzepatide Studied range: 2.5–15 mg](https://pepvault.app/peptides/tirzepatide)
- [Liraglutide Studied range: 0.6–3 mg](https://pepvault.app/peptides/liraglutide)

## Related guides

- Guide · GLP-1s

  ### [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)

  The longest GLP-1 trials ran 2 to 5.4 years, and heart events and deaths were the same or lower on the drug. The long-term risks, the thyroid warning, cycling.

  Read the guide
- Guide · GLP-1s

  ### [Retatrutide and cancer: what the warning and the studies say](https://pepvault.app/guides/retatrutide-and-cancer)

  Retatrutide and cancer: where the GLP-1 thyroid warning comes from, who the trials left out, the cancers they counted, and what studies of the class found.

  Read the guide
- Guide · GLP-1s

  ### [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)

  Ozempic and Wegovy side effects from the labels' trials, drug against placebo: nausea and the rest, when they start, how many days they last, and what helps.

  Read the guide
- Guide · GLP-1s

  ### [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)

  Mounjaro and Zepbound side effects at 5, 10 and 15 mg against placebo, from the labels' trial tables: when they show up, how many stopped, and what helps.

  Read the guide
- Guide · Getting started

  ### [Blood tests before starting a GLP-1 or a peptide, and which to repeat](https://pepvault.app/guides/blood-tests-before-starting)

  What the FDA labels for Ozempic, Wegovy, Mounjaro, Zepbound, tesamorelin, growth hormone and testosterone test before the first dose and which they repeat.

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)
- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)

### Studies

- [Semaglutide: 11.85% more weight loss than placebo without diabetes](https://pepvault.app/research/semaglutide-tan-2022)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 31 studies](https://pepvault.app/research#semaglutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Liraglutide vs Semaglutide](https://pepvault.app/peptides/compare/liraglutide-vs-semaglutide)
- [Semaglutide vs Dulaglutide](https://pepvault.app/peptides/compare/semaglutide-vs-dulaglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)
- [Constipation on Ozempic, Mounjaro or Zepbound: how common, and what helps](https://pepvault.app/guides/constipation-on-a-glp-1)
- [Nausea on Ozempic, Wegovy, Mounjaro or Zepbound: when it peaks and what helps](https://pepvault.app/guides/nausea-on-a-glp-1)
- [Headaches on a GLP-1: how common they were in the trials](https://pepvault.app/guides/headaches-on-a-glp-1)
- [Sulfur burps on Ozempic or Mounjaro: why they happen](https://pepvault.app/guides/sulfur-burps-on-a-glp-1)
- [GLP-1s and the gallbladder: gallstones, and taking one without a gallbladder](https://pepvault.app/guides/glp-1s-and-the-gallbladder)
- [GLP-1s and the heart: heart rate, blood pressure and the SELECT trial](https://pepvault.app/guides/glp-1s-and-the-heart)
- [Retatrutide and cancer: what the warning and the studies say](https://pepvault.app/guides/retatrutide-and-cancer)
- [Retatrutide and muscle loss: what the studies measured](https://pepvault.app/guides/retatrutide-and-muscle)

### Terms on this page

- [Unit (on a syringe)](https://pepvault.app/glossary/syringe-units)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Contraindication](https://pepvault.app/glossary/contraindication)
- [Boxed warning](https://pepvault.app/glossary/boxed-warning)
- [Confidence interval](https://pepvault.app/glossary/confidence-interval)
- [Incretin](https://pepvault.app/glossary/incretin)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
